Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2024-03-19 00:00:00 ET · period of report 2024-03-15 · accession 0001689375-24-000017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-19 | 2024-03-15 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +9,000 | 83.2K | +12% | +$18.9K |
| D | 2024-03-19 | 2024-03-15 | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $0.00 | -9,000 | 43.2K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | M | A | 9,000 | $2.10 | 83,170 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-03-15 | M | D | 9,000 | $0.00 | 43,157 | D | $2.10 · — to 2030-11-10 | 9,000 Common Stock | (F1) 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. |